Distinguished in Alcoholic Cirrhosis

Dr. Nikolaos Pyrsopoulos

Hepatology
New York University
550 1st Ave, 
New York, NY 
29 Years of Experience
Distinguished in Alcoholic Cirrhosis
New York University
550 1st Ave, 
New York, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Nikolaos Pyrsopoulos is a Hepatologist in New York, New York. Dr. Pyrsopoulos has been practicing medicine for over 29 years and is rated as a Distinguished provider by MediFind in the treatment of Alcoholic Cirrhosis. His top areas of expertise are Liver Failure, Hepatitis, Hepatorenal Syndrome, Liver Transplant, and Endoscopy.

His clinical research consists of co-authoring 98 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hepatology
Licenses
Internal Medicine in NY
Hospital Affiliations
Nyu Langone Hospitals
Morristown Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Clover Health
  • INSURANCE PLAN
  • MEDICARE MAPD
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

NEW YORK UNIVERSITY
550 1st Ave, New York, NY 10016
Other Locations
PRACTICE ASSOCIATES MEDICAL GROUP
33 Overlook Rd, Summit, NJ 07901
NEW YORK UNIVERSITY
111 Broadway, New York, NY 10006

Additional Areas of Focus

Dr. Pyrsopoulos has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Non-Alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis (NASH)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase 2, Open-label, Multicenter Study to Investigate the Efficacy, Safety, and Pharmacokinetics of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Patients With Previously Treated Hepatocellular Unresectable Carcinoma
A Phase 2, Open-label, Multicenter Study to Investigate the Efficacy, Safety, and Pharmacokinetics of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Patients With Previously Treated Hepatocellular Unresectable Carcinoma
Enrollment Status: Completed
Publish Date: October 26, 2024
Intervention Type: Drug
Study Drug: Tislelizumab
Study Phase: Phase 2
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
Enrollment Status: Terminated
Publish Date: October 01, 2024
Intervention Type: Drug
Study Drug: Obeticholic Acid
Study Phase: Phase 3
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
Enrollment Status: Completed
Publish Date: October 23, 2023
Intervention Type: Drug
Study Drug: Obeticholic acid
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Decompensated Non-Alcoholic Steatohepatitis (NASH) Cirrhosis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Decompensated Non-Alcoholic Steatohepatitis (NASH) Cirrhosis
Enrollment Status: Unknown
Publish Date: March 19, 2019
Intervention Type: Drug
Study Drug: Emricasan
Study Phase: Phase 2
A Randomized, Open-Label, Multicenter, Controlled, Pivotal Study to Assess Safety and Efficacy of ELAD in Subjects With Alcohol-Induced Liver Decompensation (AILD)
A Randomized, Open-Label, Multicenter, Controlled, Pivotal Study to Assess Safety and Efficacy of ELAD in Subjects With Alcohol-Induced Liver Decompensation (AILD)
Enrollment Status: Terminated
Publish Date: January 25, 2019
Intervention Type: Biological, Other
Study Phase: Phase 3
68Gallium Citrate Imaging in Newly Diagnosed Hepatocellular Carcinoma
68Gallium Citrate Imaging in Newly Diagnosed Hepatocellular Carcinoma
Enrollment Status: Unknown
Publish Date: January 03, 2019
Intervention Type: Drug
Study Drug: 68Gallium Citrate
Study Phase: Phase 2
View 5 Less Clinical Trials

98 Total Publications

Real-world use of terlipressin in cirrhosis and acute kidney injury: frequent use beyond hepatorenal syndrome.
Real-world use of terlipressin in cirrhosis and acute kidney injury: frequent use beyond hepatorenal syndrome.
Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Published: May 10, 2025
Similar Doctors
Distinguished in Alcoholic Cirrhosis
Dr. Gene Im
Hepatology
Distinguished in Alcoholic Cirrhosis
Dr. Gene Im
Hepatology

Trustees Of Columbia University In The City Of New York

622 W 168th St, 
New York, NY 
 (7.0 miles away)
212-305-9876
Languages Spoken:
English
See accepted insurances

Gene Im is a Hepatologist in New York, New York. Dr. Im is rated as an Elite provider by MediFind in the treatment of Alcoholic Cirrhosis. His top areas of expertise are Hepatitis, Alcoholic Cirrhosis, Liver Failure, Liver Transplant, and Hepato-Pancreato-Biliary Surgery.

Distinguished in Alcoholic Cirrhosis
Dr. Sanjaya Satapathy
Hepatology
Distinguished in Alcoholic Cirrhosis
Dr. Sanjaya Satapathy
Hepatology

North Shore-Lij Medical PC

300 Community Dr, 
Manhasset, NY 
 (14.5 miles away)
516-562-3058
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Sanjaya Satapathy is a Hepatologist in Manhasset, New York. Dr. Satapathy is rated as an Elite provider by MediFind in the treatment of Alcoholic Cirrhosis. His top areas of expertise are Spontaneous Bacterial Peritonitis, Nonalcoholic Steatohepatitis (NASH), Non-Alcoholic Fatty Liver Disease, Liver Transplant, and Endoscopy.

Distinguished in Alcoholic Cirrhosis
Dr. Joseph Odin
Hepatology
Distinguished in Alcoholic Cirrhosis
Dr. Joseph Odin
Hepatology

Icahn School Of Medicine At Mount Sinai

5 E 98th St, 
New York, NY 
 (3.3 miles away)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Joseph Odin is a Hepatologist in New York, New York. Dr. Odin is rated as a Distinguished provider by MediFind in the treatment of Alcoholic Cirrhosis. His top areas of expertise are Primary Biliary Cholangitis, Cholangitis, Hepatitis, Endoscopy, and Liver Transplant.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Pyrsopoulos's expertise for a condition
ConditionClose
View All 14 Advanced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile